Phase I Study of Safety and Pharmacokinetics of Topical Solution in Subjects With Androgenetic Alopecia

Inclusion Criteria: Males between age 18 to 65 years, in general good health. Good health is defined as a subject without any active diseases. Not included in active diseases are: * Migraines * Non-hospitalized depression o Asthma * Cholecystectomy * Gilbert's syndrome * Clinical diagnosis of AGA with grade II to VI hair loss on Norwood Hamilton Classification System * Subjects of any Fitzpatrick skin type or race provided their degree of skin pigmentation does not, in the Investigator's opinion, interfere with study assessments. * No known allergy to ANR-001.1 or any of its components. * Subject is willing to avoid extensive sun exposure, phototherapy, or use of tanning salon for the duration of the study. Exclusion Criteria: If subjects have a BMI outside of the range of 18-35kg/m2 * Subjects using a minoxidil product (e.g., Rogaine or generic Rogaine) or a latanoprost product (e.g., Xalatan or generic Xalatan) within 30 days of the start of Day 1 of the study. * Subjects whose vital signs, ECG, safety labs or physical exam results are clinically significant in the opinion of the investigator. * Subjects have a skin condition that, in the Investigators opinion, could interfere with study assessment or put the subject at undue risk by study participation. * Subjects with an active or recent (within 30 days before Day 1) disease or infection, or chronic dermatological condition (eczema, psoriasis, infection, etc.). * Subjects with known or suspected hypersensitivity or allergic reaction to any of the active or inactive components of the test treatment. * Current enrollment in any other investigational medication (drug) study within the 4 weeks prior to study initiation.